CL2017000063A1 - Vacunas contra virus influenza y usos de las mismas - Google Patents

Vacunas contra virus influenza y usos de las mismas

Info

Publication number
CL2017000063A1
CL2017000063A1 CL2017000063A CL2017000063A CL2017000063A1 CL 2017000063 A1 CL2017000063 A1 CL 2017000063A1 CL 2017000063 A CL2017000063 A CL 2017000063A CL 2017000063 A CL2017000063 A CL 2017000063A CL 2017000063 A1 CL2017000063 A1 CL 2017000063A1
Authority
CL
Chile
Prior art keywords
influenza viruses
vaccines against
against influenza
vaccines
viruses
Prior art date
Application number
CL2017000063A
Other languages
English (en)
Inventor
Antonietta Impagliazzo
Jan Wilem Meijberg
Katarina Radosevic
Michelle Wagner
Zhaoqing Ding
Original Assignee
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55063615&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017000063(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv
Publication of CL2017000063A1 publication Critical patent/CL2017000063A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08RNA viruses
    • C07K14/11Orthomyxoviridae, e.g. influenza virus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10RNA viruses
    • C07K16/108Orthomyxoviridae (F), e.g. influenza virus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55577Saponins; Quil A; QS21; ISCOMS
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2017000063A 2014-07-10 2017-01-10 Vacunas contra virus influenza y usos de las mismas CL2017000063A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14176451 2014-07-10
US201462062746P 2014-10-10 2014-10-10
EP14195133 2014-11-27

Publications (1)

Publication Number Publication Date
CL2017000063A1 true CL2017000063A1 (es) 2017-12-15

Family

ID=55063615

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000063A CL2017000063A1 (es) 2014-07-10 2017-01-10 Vacunas contra virus influenza y usos de las mismas

Country Status (16)

Country Link
US (2) US10111944B2 (es)
EP (2) EP3587442A1 (es)
JP (1) JP6735269B2 (es)
KR (1) KR102461538B1 (es)
CN (1) CN106661091B (es)
AU (1) AU2015286721B2 (es)
BR (1) BR112017000257A2 (es)
CA (1) CA2952351C (es)
CL (1) CL2017000063A1 (es)
EA (1) EA038400B1 (es)
MX (1) MX378904B (es)
MY (1) MY187261A (es)
PE (1) PE20170290A1 (es)
PH (1) PH12016502500B1 (es)
SG (1) SG11201610443WA (es)
WO (1) WO2016005480A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010117786A1 (en) 2009-03-30 2010-10-14 Mount Sinai School Of Medicine Of New York University Influenza virus vaccines and uses thereof
EP3566714A1 (en) 2011-11-28 2019-11-13 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
SG11201504728RA (en) 2012-12-18 2015-07-30 Icahn School Med Mount Sinai Influenza virus vaccines and uses thereof
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
EA034639B1 (ru) 2013-05-30 2020-03-02 Янссен Вэксинс Энд Превеншн Б.В. Вакцины против вируса гриппа и их применения
MX378904B (es) 2014-07-10 2025-03-10 Janssen Vaccines & Prevention Bv Vacunas para virus influenza y usos de las mismas.
EA035375B1 (ru) 2014-07-10 2020-06-03 Янссен Вэксинс Энд Превеншн Б.В. Вакцины против вируса гриппа и их применения
US10736956B2 (en) 2015-01-23 2020-08-11 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
MX2018015755A (es) 2016-06-15 2019-08-29 Icahn School Med Mount Sinai Proteinas de hemaglutinina de virus de influenza y usos de las mismas.
US11254733B2 (en) 2017-04-07 2022-02-22 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
LT3743106T (lt) 2018-01-23 2022-09-26 Janssen Vaccines & Prevention B.V. Gripo viruso vakcinos ir jų panaudojimo būdai
CA3104297A1 (en) 2018-06-21 2019-12-26 Icahn School Of Medicine At Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
US12545718B2 (en) 2019-04-24 2026-02-10 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
CA3152957A1 (en) 2019-09-05 2021-03-11 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
US12577279B2 (en) * 2019-10-15 2026-03-17 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
WO2023198815A1 (en) 2022-04-14 2023-10-19 Janssen Vaccines & Prevention B.V. Sequential administration of adenoviruses

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
EP2450377A1 (en) 2006-09-07 2012-05-09 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof
WO2010117786A1 (en) 2009-03-30 2010-10-14 Mount Sinai School Of Medicine Of New York University Influenza virus vaccines and uses thereof
CA2761648C (en) 2009-05-11 2019-03-12 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
CN102939103A (zh) 2010-03-30 2013-02-20 西奈山医学院 流感病毒疫苗及其应用
US8961978B2 (en) 2011-07-14 2015-02-24 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza A viruses of phylogenetic group 1 and phylogenetic group 2 and influenza B viruses
EP3566714A1 (en) * 2011-11-28 2019-11-13 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
EA034639B1 (ru) * 2013-05-30 2020-03-02 Янссен Вэксинс Энд Превеншн Б.В. Вакцины против вируса гриппа и их применения
EA035375B1 (ru) 2014-07-10 2020-06-03 Янссен Вэксинс Энд Превеншн Б.В. Вакцины против вируса гриппа и их применения
MX378904B (es) 2014-07-10 2025-03-10 Janssen Vaccines & Prevention Bv Vacunas para virus influenza y usos de las mismas.

Also Published As

Publication number Publication date
US20170209564A1 (en) 2017-07-27
AU2015286721A1 (en) 2016-12-22
EP3166962B1 (en) 2019-08-21
WO2016005480A1 (en) 2016-01-14
CN106661091B (zh) 2020-10-30
EA038400B1 (ru) 2021-08-23
CA2952351A1 (en) 2016-01-14
SG11201610443WA (en) 2017-01-27
JP2017521425A (ja) 2017-08-03
MX2017000394A (es) 2017-11-30
MY187261A (en) 2021-09-16
CN106661091A (zh) 2017-05-10
MX378904B (es) 2025-03-10
BR112017000257A2 (pt) 2017-10-31
EA201692541A1 (ru) 2017-05-31
US10111944B2 (en) 2018-10-30
US20190015500A1 (en) 2019-01-17
PE20170290A1 (es) 2017-03-26
JP6735269B2 (ja) 2020-08-05
KR20170030590A (ko) 2017-03-17
PH12016502500A1 (en) 2017-03-22
EP3587442A1 (en) 2020-01-01
CA2952351C (en) 2023-10-17
AU2015286721B2 (en) 2019-11-21
EP3166962A1 (en) 2017-05-17
PH12016502500B1 (en) 2024-01-17
KR102461538B1 (ko) 2022-10-31
US10328144B2 (en) 2019-06-25

Similar Documents

Publication Publication Date Title
CL2017000064A1 (es) Vacunas contra virus influenza y usos de las mismas
CL2017000063A1 (es) Vacunas contra virus influenza y usos de las mismas
PT3718565T (pt) Vacinas contra vírus respiratórios
IL259077A (en) Vaccines against hepatitis b virus
EP3538146A4 (en) INFLUENZA VACCINE
EP3463447A4 (en) INFLUENZA VIRUS PROTECTION Vaccines
EP3659614C0 (en) ONCOLYTIC VACCINIA VIRUS
EP3490574A4 (en) EXPRESSION OF PTEN-LONG WITH ONCOLYTIC VIRUSES
CL2016002413A1 (es) Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso
MA46317A (fr) Vaccin contre le virus respiratoire syncytial
ZA201700952B (en) Indoles for use in influenza virus infection
EP2934581A4 (en) INFLUENZA VIRUS VACCINES AND USES THEREOF
DK3191489T3 (da) Pyrrolopyrimidiner til anvendelse ved influenzavirusinfektion
EP3247389A4 (en) INFLUENZAVIRUSSCHUTZIMPFPLÄNE
LT3197489T (lt) Būdai ir kompozicijos, skirti indukuoti apsauginį imunitetą prieš žmogaus imunodeficito viruso infekciją
ZA201509229B (en) Influenza virus vaccines and uses thereof
SG11201701256RA (en) Vaccine compositions against dengue virus diseases
EP2969005A4 (en) WAXED INFLUENZA VIRUSES AND VACCINES
IL249500A0 (en) Rhinovaccination system of influenza vaccine
PT3342422T (pt) Vacinas contra o vírus da tilápia do lago
SG11201704942QA (en) Dengue virus vaccine compositions and methods of use thereof
BR112017004452A2 (pt) vírus atenuado, arbovírus atenuado, seus usos, composição de vacina, método de produção de um genoma de vírus atenuado, método de produção de um arbovírus atenuado e genoma de arbovírus atenuado
EP3562498A4 (en) INFLUENZA VACCINES
MA45994A (fr) Vaccins contre des virus
IL249705B (en) Influenza virus vaccines and their uses